» Articles » PMID: 8704234

Low Levels of Erythroid and Myeloid Progenitors in Thrombopoietin-and C-mpl-deficient Mice

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1996 Aug 1
PMID 8704234
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Thrombopoietin (TPO), the ligand for the c-mpl receptor, has been shown to be the major regulator of platelet production. Mice deficient in either c-mpl or TPO generated by homologous recombination show a dramatic decrease in platelet counts, but other blood cell counts are normal. Because TPO treatment of myelosuppressed mice not only enhances the recovery of platelets but also accelerates erythroid recovery, we investigated the levels of myeloid and erythroid progenitor cells in TPO-or c-mpl-deficient mice. Our results show that the number of megakaryocyte, granulocyte-macrophage, erythroid, and multilineage progenitors are significantly reduced in the bone marrow, spleen, and peripheral blood of either TPO-or c-mpl-deficient mice. Administration of recombinant murine TPO to TPO-deficient mice and control littermate mice significantly increased the absolute number of myeloid, erythroid, and mixed progenitors in bone marrow and spleen. This increase was especially apparent in TPO-deficient mice where numbers were increased to a level greater than in diluent-treated control mice and approached or equaled that in the TPO-treated control mice. Moreover, TPO-administration greatly increased the number of circulating progenitors as well as platelets in both TPO-deficient and control mice. Furthermore, the megakaryocytopoietic activity of other cytokines in the absence of a functional TPO or c-mpl gene was shown both in vitro and in vivo.

Citing Articles

Thrombopoietin level predicts the response to avatrombopag treatment for persistent thrombocytopenia after haploidentical haematopoietic stem cell transplantation.

Fu H, Lv M, Liu H, Sun Y, Zhang Y, Mo X Bone Marrow Transplant. 2023; 58(12):1368-1376.

PMID: 37679646 DOI: 10.1038/s41409-023-02100-6.


Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis.

Tsutsumi N, Masoumi Z, James S, Tucker J, Winkelmann H, Grey W Cell. 2023; 186(19):4189-4203.e22.

PMID: 37633268 PMC: 10528194. DOI: 10.1016/j.cell.2023.07.037.


Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies.

Kuter D Haematologica. 2022; 107(6):1243-1263.

PMID: 35642485 PMC: 9152964. DOI: 10.3324/haematol.2021.279512.


CXCL15/Lungkine has suppressive activity on proliferation and expansion of multi-potential, erythroid, granulocyte and macrophage progenitors in S-phase specific manner.

Broxmeyer H, Cooper S, Ropa J Blood Cells Mol Dis. 2021; 91:102594.

PMID: 34520986 PMC: 9231597. DOI: 10.1016/j.bcmd.2021.102594.


In and out: Traffic and dynamics of thrombopoietin receptor.

Roy A, Shrivastva S, Naseer S J Cell Mol Med. 2021; 25(19):9073-9083.

PMID: 34448528 PMC: 8500957. DOI: 10.1111/jcmm.16878.